

BMJ Open Cost-utility and budget impact analyses of the use of NEPA for chemotherapy-induced nausea and vomiting prophylaxis in Italy

Umberto Restelli,^{1,2} Gabriella Saibene,³ Patrizia Nardulli,⁴ Roberta Di Turi,⁵ Erminio Bonizzoni,⁶ Francesca Scolari,¹ Tania Perrone,⁷ Davide Croce,^{1,2} Luigi Celio³

To cite: Restelli U, Saibene G, Nardulli P, *et al.* Cost-utility and budget impact analyses of the use of NEPA for chemotherapy-induced nausea and vomiting prophylaxis in Italy. *BMJ Open* 2017;7:e015645. doi:10.1136/bmjopen-2016-015645

► Prepublication history and additional material are available. To view these files please visit the journal online (<http://dx.doi.org/10.1136/bmjopen-2016-015645>).

Received 23 December 2016

Revised 18 May 2017

Accepted 30 June 2017

ABSTRACT

Objective To evaluate the efficiency of resources allocation and sustainability of the use of netupitant+palonosetron (NEPA) for chemotherapy-induced nausea and vomiting (CINV) prophylaxis assuming the Italian National Health Service (NHS) perspective. A published Markov model was adapted to assess the incremental cost-utility ratio of NEPA compared with aprepitant (APR) + palonosetron (PALO), fosaprepitant (fAPR) + PALO, APR + ondansetron (ONDA), fAPR + ONDA in patients receiving a highly emetogenic chemotherapy (HEC) and with APR + PALO and fAPR + PALO in patients receiving a moderately emetogenic chemotherapy (MEC).

Setting Oncology hospital department in Italy.

Methods A Markov model was used to determine the impact of NEPA on the budget of the Italian NHS on a 5-day time horizon, corresponding to the acute and delayed CINV prophylaxis phases. Direct medical costs considered were related to antiemetic drugs, adverse events management, CINV episodes management. Clinical and quality of life data referred to previously published works. The budget impact analysis considered the aforementioned therapies plus PALO alone (for HEC and MEC) on a 5-year time horizon, comparing two scenarios: one considering the use of NEPA and one not considering its use.

Primary and secondary outcome measures Incremental cost per quality adjusted life year (QALY) and differential economic impact for the Italian NHS between the two scenarios considered.

Results NEPA is more effective and less expensive (dominant) compared with APR + PALO (for HEC and MEC), fAPR + PALO (for HEC and MEC), APR + ONDA (for HEC), fAPR + ONDA (for HEC). The use of NEPA would lead to a 5-year cost decrease of €63.7 million (€42.7 million for HEC and €20.9 million for MEC).

Conclusions NEPA allows an efficient allocation of resources for the Italian NHS and it is sustainable, leading to a cost decrease compared with a scenario which does not consider its use.

INTRODUCTION

Nausea and vomiting still remain among the most feared side effects of cancer

Strengths and limitations of this study

- To the best of our knowledge, the economic analysis presented in the article is the first one concerning NEPA within the Italian context.
- The analysis conducted assessed the efficiency in resources allocation and the sustainability of antiemetic prophylaxis for patients receiving chemotherapy, which is a relevant topic in a field, as that of Oncology, in which a synthesis of effectiveness and cost containment strategies is necessary to allow accessibility of high-cost therapies.
- The generalisability of results might be limited, since the analysis was conducted concerning the Italian context.
- The Markov model used does not allow a probabilistic sensitivity analysis to be performed.

chemotherapy.¹ A suboptimal control of chemotherapy-induced nausea and vomiting (CINV) can lead to delays in treatment and increase healthcare costs due to increased medication use, hospital admissions and longer hospital stays.² Ultimately, the consequences of uncontrolled CINV can adversely impact on patient's quality of life.³

The intensity, onset and duration of CINV depend on the emetogenic potential and dose of anticancer agents as well as on individual patient characteristics.² Highly emetogenic chemotherapy (HEC) such as cisplatin-containing regimens can result in acute emesis (within 24 hours after chemotherapy administration) in more than 90% of patients without antiemetics.⁴ Agents such as carboplatin, oxaliplatin, cyclophosphamide or anthracyclines (eg, doxorubicin or epirubicin) carry a moderate emetic risk (incidence of acute emesis without antiemetics, 30%–90%) as single agents but their



CrossMark

For numbered affiliations see end of article.

Correspondence to

Dr Umberto Restelli;
urestell@gmail.com

combination may increase emetic risk substantially.⁴ The current guideline-recommended prophylaxis for patients receiving HEC is a three-drug regimen including a 5-HT₃ receptor antagonist (5-HT₃RA), dexamethasone and a neurokinin-1 receptor antagonist (NK-1RA).⁵⁻⁷ In patients receiving moderately emetogenic chemotherapy (MEC), the combination of a 5-HT₃RA and dexamethasone is the current guideline-recommended regimen for the prevention of CINV.^{4 6 7} It also should be noted that some guidelines recommend palonosetron (PALO) as the preferred 5-HT₃RA in the setting of MEC.^{6 7} More recently, it has been recognised that although carboplatin is graded as moderately emetogenic in evidence-based guidelines, the emetogenic potential of this agent is at the higher end of MEC.⁸ Accordingly, the updated guidelines from the Multinational Association of Supportive Care in Cancer now recommend a three-drug regimen for the optimal control of CINV following carboplatin-based chemotherapy.⁴

Emerging from the most recent research on CINV is netupitant+palonosetron (NEPA), the first antiemetic combination drug developed. NEPA is a single oral fixed-dose combination of netupitant, a new NK-1RA with a long half life of 90 hours and PALO.⁹ PALO is a second-generation 5-HT₃RA that has greater 5-HT₃ receptor binding affinity and longer plasma elimination half life compared with older antagonists and a unique interaction with the 5-HT₃ receptor at the molecular level. The unique pharmacology of PALO is thought to partly explain its improved efficacy against delayed CINV.¹⁰ It must be pointed out that NEPA is capable of enhancing the convenience of administering antiemetic prophylaxis targeted at two critical molecular pathways involved in the pharmacology of CINV.² Large-scale clinical trials have demonstrated that NEPA plus dexamethasone was superior to the control combination of PALO and dexamethasone, as measured by the proportion of patients with a complete response (CR) throughout the 5-day period after the first cycle of either cisplatin-containing chemotherapy or the high-emetic-risk combination of an anthracycline and cyclophosphamide (AC) in patients with breast cancer.^{11 12} It must be pointed out that the combination of AC has historically been considered a MEC regimen but because it is commonly administered to females with breast cancer, the emetogenic risk is substantially increased due to the additional patient-related risk factors (i.e., gender and age).^{2 5} Since an effective and convenient antiemetic prophylaxis that preserves benefit over repeated cycles of chemotherapy is a clinically important topic,^{13 14} a double-blind, randomised phase III trial investigated the safety and efficacy of NEPA in this challenging setting.¹⁵ This study demonstrated sustained efficacy over repeated cycles of HEC or MEC in patients treated with NEPA. More recently, a multiple-cycle extension of the phase III trial with NEPA in patients with breast cancer receiving AC also showed the sustained benefit of NEPA over multiple cycles of therapy.¹⁶

The assessment of the effectiveness and safety of new treatments are two of the key dimensions that should be evaluated in the assessment of new technology. However, further impacts of the introduction of a new medicine on health services should be assessed, assuming a multidisciplinary approach as that of Health Technology Assessment (HTA).¹⁷ Within a complete HTA, the 'costs and economic evaluation' represents one of the key dimensions to be considered. The assessment of this dimension is crucial considering the context in which National Health Services worldwide are operating, characterised by a persistent stress on national healthcare budgets (i.e., austerity measures)¹⁸ and the need to make new and effective health technologies available to patients. Due to a lack of economic evaluation within the Italian National Health Service and the aforementioned considerations, the analysis presented aimed at evaluating the efficiency of resources allocation and sustainability of the use of NEPA in the management of the prophylaxis of CINV in the Italian context, both for HEC (cisplatin) and MEC (AC and non-AC MEC), through a cost-utility analysis and a budget impact analysis.

METHODS

Cost-utility analysis

Cost-utility model, perspective and model outcomes

The assessment of the incremental cost-utility ratio (ICUR) of the use of NEPA versus the comparators was performed using a Markov model already used in an analysis presented in literature,¹⁹ whose structure is reported in figure 1. The perspective assumed in the analysis was that of the Italian National Health Service (NHS).

The model considers a single cycle of chemotherapy, with a 5-day time horizon for CINV management (no discount rate was used due to the time horizon considered) and the possibility for patients to transit through three mutually exclusive health states: 'complete protection (CP)' (absence of emetic episodes, no significant nausea (<25 mm on a Visual Analogue Scale) and no use of rescue medication), 'CR' (absence of emetic episodes and no use of rescue medication) and 'incomplete




Figure 1 Markov model structure. CINV, chemotherapy-induced nausea and vomiting.

response' (patients experiencing emesis and requiring rescue medication).

Patients who start an antiemetic prophylaxis for CINV may reach a 'CP', 'CR' or 'Incomplete response' state in the acute phase (day 1). On day 5, the distribution of patients among the health states is based on the effectiveness parameters of the overall phase (day 1–5). During the second, third and fourth day, the distribution of patients among the health states was calibrated using linear interpolation between the response proportion of the acute and overall phase.

In the delayed phase (days 2–5), patients may remain in the same health state of the previous cycle or transit to 'CR' from the 'CP' state and transit to 'Incomplete response' state from the 'CP' and 'CR' health states.¹⁹

The transition probabilities depend on the effectiveness parameters considered per treatment in the acute phase and delayed phase.

During the 5-day time horizon of the analysis, patients may experience adverse events, with a probability derived from clinical trials and published studies.

The outcome of the model is the ICUR of the use of NEPA compared with each comparator. This represents the incremental cost associated with each additional unit of utility (either a QALY or a quality adjusted life day (QALD)).

Interventions, eligible population and time horizon

The cost-utility analysis was conducted considering the use of NEPA both in patients receiving HEC and MEC, comparing the use of the new drug with the administration of NK1-RA (aprepitant (APR) or fosaprepitant (fAPR)) in combination with 5HT3-RA (PALO or ondansetron (ONDA)). The time horizon considered in the analysis is of 5 days.

Model parameters

Clinical efficacy analysis

The estimates of changes in the probability of CINV control over repeated cycles of HEC or MEC were obtained from a double-blind, randomised trial of NEPA-based (day 1: NEPA plus dexamethasone) and APR-based (day 1: APR 125 mg, PALO 0.50 mg and dexamethasone; days 2–3: APR 80 mg per day) antiemetic regimens for the prevention of CINV among chemo-naïve, adult patients with a malignancy who were scheduled to receive repeated consecutive cycle of chemotherapy. The study design has been previously described in detail.¹⁵ Four hundred and twelve patients (for a total of 1961 chemotherapy cycles, 1446 in the NEPA arm and 515 in the APR + PALO arm) were eligible, being scheduled to receive HEC or non-AC MEC regimens. The goal of the study was to characterise the safety profile of NEPA over at least six consecutive cycles of chemotherapy. Efficacy end points were CR (defined as no emesis and no rescue medication) and CP (defined as no emesis, no rescue medication and no significant nausea (Visual Analogue Scale score of <25 mm)) during the acute (within 24 hours after chemotherapy administration) and overall (within 5 days

after chemotherapy initiation) periods after all planned chemotherapy cycles.

The proportion of patients with either CR or CP was used to evaluate efficacy across acute and overall phases. To accurately determine protection against CINV over multiple consecutive cycles, a generalised mixed linear model was used. In detail, the overall proportions and proportions at each chemotherapy cycle of CR and CP, with associated two-tailed 95% CIs, were estimated using a model with an identity link function (non-canonical link function), binomial probability distribution and parameterised with treatment group, cycle and treatment-by-cycle interaction as fixed effects.²⁰ Overall CR and CP proportions were estimated directly from the generalised mixed linear model as least-square mean of the fixed effect 'treatment group'. Since incomplete profiles may occur because of the physician's decision to administer fewer than six cycles or because of drop-out events, the mixed model was parameterised using a full Toeplitz variance-covariance matrix. This should represent a suitable choice to take into account correlation across repeated measures (cycles) and to adjust for the potential bias caused by incomplete profiles. Computations were performed using the GLIMMIX procedure of SAS version 9.4.

The adjusted proportion estimates of achieving CINV control in each treatment arm during the acute and overall periods among patients receiving a cycle of HEC or MEC are presented in the online supplementary material.

The effectiveness parameters considered for NEPA are reported in [table 1](#), along with the Odds Ratios (ORs) for each comparator, derived from the results of the NEPA study in HEC¹¹ and from the results of NEPA study in MEC¹²). The effectiveness parameters of NEPA, are based on the following clinical trials: the NEPA study in patients receiving either HEC or MEC¹⁵ and within the sensibility analysis, the NEPA studies in HEC¹¹ and MEC.¹²

Starting from the effectiveness results of NEPA derived from the aforementioned clinical trial, ORs were calculated to be incorporated in the model for each comparator, as reported in [table 1](#). Due to the clinical non-inferiority of fAPR compared with APR and to a lack of data referred to therapies that consider the use of fAPR, the same ORs of APR based therapies were considered.

The adverse events considered were constipation, headache, fatigue, injection site's reaction, anorexia. The incidence of each adverse event is reported in [table 2](#).

Costs

The costs considered in the analysis are direct medical costs referred to year 2016 related to the antiemetic therapy administered to patients, the management of adverse events and the management of CINV episodes.

The costs related to each antiemetic drug, including the mandatory discount for the National Health Service are presented in [table 3](#), along with the cost per adverse event management and CINV episode management.

Table 1 NEPA effectiveness and ORs considered in the model

| | | | Effectiveness | | NEPA versus | |
|-----|---------------|---------------------|---------------|------------|-------------|-------------|
| | | | NEPA | APR + PALO | PALO*,† | APR + ONDA† |
| HEC | Acute phase | Complete response | 92.8 | 1.952‡ | 7.540 | 3.602 |
| | | Complete protection | 90.0 | 2.536‡ | 4.619 | 3.753 |
| | Overall phase | Complete response | 83.6 | 1.982‡ | 2.647 | 1.333 |
| | | Complete protection | 78.0 | 2.064‡ | 2.102 | 1.345 |
| MEC | Acute phase | Complete response | 95.7 | 0.956‡ | 1.345 | N/A |
| | | Complete protection | 92.8 | 1.099‡ | 1.084 | N/A |
| | Overall phase | Complete response | 88.1 | 1.248‡ | 1.450 | N/A |
| | | Complete protection | 83.5 | 1.336‡ | 1.281 | N/A |

Due to the clinical non-inferiority of fAPR compared with APR and to a lack of data referred to therapies that imply the use of fAPR, the same ORs of APR based therapies were considered for fAPR + PALO and fAPR + ONDA.

*Considered for the budget impact analysis.

†HEC: data calculated on the basis of the results from reference [11]; MEC: data calculated on the basis of the results of reference [12].

‡Data calculated on the basis of the results from reference [15].

APR, aprepitant; fAPR, fosaprepitant; HEC, highly emetogenic chemotherapy; MEC, moderately emetogenic chemotherapy; ONDA, ondansetron; PALO, palonosetron.

The cost for the management of adverse events and CINV episode are based on real clinical practice, as emerged from interviews conducted with a Key Opinion Leader clinician referring to the Department of Medical Oncology of an oncology research hospital ('Istituto di Ricovero e Cura a Carattere Scientifico') based in Milan. CINV management took into consideration a weighted mean cost which considered hospitalisations, rescue medication and outpatient activities. The management of adverse events took into consideration hospitalisations, outpatient activities and drugs. Assuming the Italian National Health Service point of view, all out-of-pocket expenditures for the management of adverse

events were not considered, leading to cost equal to €0 for three of the adverse events considered in the analysis.

A further cost of €20.66 (reimbursement due to a specialist visit) was considered for intravenous administration of drugs, due to the hospital resources-data-word-spacing="0.63w" increased use compared with oral administration of therapies.

Utility

Utility was measured considering the QALYs gained by patients due to the use of antiemetic therapies. Due to the short-term time horizon considered, to increase the readability of the results, QALDs were used.

Table 2 Adverse events' incidence

| Therapy | Chemotherapy | Constipation | Headache | Fatigue | Injection site's reaction | Anorexia |
|-------------|--------------|--------------------|--------------------|---------------------|---------------------------|--------------------|
| NEPA | HEC | 2.3% ^a | 1.0% ^a | 4.0% ^b | 0.0% ^c | 0.7% ^d |
| | MEC | 2.3% ^a | 1.0% ^a | 4.0% ^b | 0.0% ^c | 0.7% ^d |
| APR + PALO | HEC | 0.0% ^e | 1.0% ^e | 1.4% ^e | 0.0% ^f | 2.0% ^e |
| | MEC | 0.0% ^e | 1.0% ^e | 1.4 % ^e | 0.0% ^f | 2.0% ^e |
| APR + ONDA | HEC | 2.4% ^e | 2.0% ^e | 1.4 % ^e | 0.0% [*] | 2.0% ^e |
| fAPR + PALO | HEC | 2.4% ^e | 2.0% ^e | 1.4 % ^e | 3.0% ^g | 2.0% ^e |
| | MEC | 2.4% ^e | 2.0% ^e | 1.4 % ^e | 35.0% ^g | 2.0% ^e |
| fAPR + ONDA | HEC | 2.4% ^e | 1.5% ^d | 1.4 % ^e | 3.0% ^g | 2.0% ^e |
| PALO | HEC | 0.0% ^{*†} | 1.5% ^{d†} | 2.0 % ^{b†} | 0.0% ^{f†} | 2.2% ^{d†} |
| | MEC | 0.0% ^{*†} | 1.5% ^{d†} | 2.0 % ^{b†} | 0.0% ^{f†} | 2.2% ^{d†} |

a. ²⁶, b. ²⁷, c. ²⁸, d. ²⁹, e. ³⁰, f. ³¹, g. ³².

*Equal to 0.0% assuming a conservative approach.

†Considered for the budget impact analysis.

APR, aprepitant; fAPR, fosaprepitant; HEC, highly emetogenic chemotherapy; MEC, moderately emetogenic chemotherapy; ONDA, ondansetron; PALO, palonosetron.

Table 3 Costs considered in the analysis

| Cost category | Cost per cycle/ event (€) | Notes | Source |
|-------------------------|---------------------------------|---|---------------|
| NEPA (oral)* | 90.46 | Netupitant 300 mg + PALO 0.5 mg capsule | 33 |
| APR (oral)* | 49.48 | 1×125 mg capsule+2×80 mg capsules | 34 |
| fAPR (intravenous)* | 48.41 | 150 mg vial | 35 |
| ONDA (intravenous)* | 23.00 | 4x8 mg vial | 36 |
| PALO (intravenous)* | 43.21 | 0.25 mg vial | 37 |
| dexamethasone | 0.12 | Cost per mg | 38 |
| CINV episode | 33.49† | | KOL interview |
| Constipation | 0.00 | | KOL interview |
| Headache | 0.00 | | KOL interview |
| Fatigue | 0.00 | | KOL interview |
| Injection site reaction | 62.52‡ | | KOL interview |
| Anorexia | 273.00§ | | KOL interview |

For HEC, dexamethasone doses considered are: 12 mg in day 1 and 8 mg on day 2, 3 and 4 for NEPA, APR + PALO, APR + ONDA; 12 mg on day 1, 8 mg in day 2 and 16 mg on day 3 and 4 for fAPR + PALO, fAPR + ONDA; 20 mg on day 1 and 16 mg on day 2, 3 and 4 for PALO.

For MEC the dexamethasone doses considered are: 12 mg on day 1 for NEPA, APR + PALO, fAPR + PALO, APR + ONDA, fAPR + ONDA and 20 mg on day 1 for PALO.

*Costs are inclusive of mandatory legal discounts.

†Equivalent to a day of hospitalisation as for 'anorexia' in 2% of patients, multiplied by 5 (the hospitalisation may be repeated up to five times); a rescue medication for 10% of patients (ondansetron + metoclopramide) and a specialist visit for 5% of patients (http://www.salute.gov.it/portale/temi/p2_6.jsp?lingua=italiano&id=3662&area=programmazioneSanitariaLea&menu=vuoto).

‡Equivalent to the cost of 1 cannula, 30 min of nursing time, 30 min of pharmacist time and for 15% of patients, a central venous catheter positioning (code 38.95) (http://www.salute.gov.it/portale/temi/p2_6.jsp?lingua=italiano&id=3662&area=programmazioneSanitariaLea&menu=vuoto).

§Equivalent to a day of hospitalisation for 'Nutrition disorders and miscellaneous metabolic disorders, >17 years old without complications (DRG 297)' (http://www.salute.gov.it/portale/temi/p2_6.jsp?lingua=italiano&id=3662&area=programmazioneSanitariaLea&menu=vuoto).

APR, aprepitant; CINV, chemotherapy-induced nausea and vomiting; fAPR, fosaprepitant; ONDA, ondansetron; PALO, palonosetron.

The quality of life of patients is affected in the model by health state and adverse events. The utility and disutility values considered are presented in [table 4](#).

Sensitivity analysis

A univariate sensitivity analysis was conducted to test the robustness of the results. The parameters changed were the cost of NEPA ($\pm 10\%$), the cost of intravenous administration (assumed to be equal to €0), the cost of adverse

events (assumed to be equal to €0 and increasing the cost of adverse events managed with out-of-pocket resources to be equal to that of the less expensive adverse event considered), the cost of CINV event ($\pm 20\%$), the utility values associated with health states ($\pm 20\%$), the disutility values associated with adverse events ($\pm 20\%$). A further sensitivity analysis was conducted varying the price of PALO to assess at which extent its variation could modify the results of the analysis.

Table 4 Utility and disutility values affecting quality of life

| Health state/adverse event | Health states' utility values/adverse events' disutility values | Source |
|----------------------------|---|--------|
| Complete protection | 0.77 | 39 |
| Complete response | 0.60 | 40 41 |
| Incomplete response | 0.26 | 40 41 |
| Constipation | -0.06 | 42 |
| Headache | -0.20 | 43 |
| Fatigue | -0.12 | 44 |
| Injection site's reaction | -0.01 | 45 |
| Anorexia | -0.18 | 46 |

Budget impact analysis

Budget impact, perspective and time horizon

The assessment of the sustainability of the use of NEPA in the Italian context was performed using a budget impact model comparing the direct medical costs related to antiemetic therapies, the management of CINV episodes and related adverse events ([table 2](#)) of two scenarios: one that did not consider the use of NEPA and one that considered the use of the new drug. The difference between the costs of the two scenarios is the impact on the budget of the Italian National Health Service due to the introduction of NEPA. The analysis was performed considering a 5-year time horizon (between 2016 and 2020).²¹

Target population, interventions' mix and market shares

The size of the target population considered was based on the incidence in Italy in 2012 of lung cancer, head and neck cancer, stomach cancer, testicular cancer and bladder cancer for patients receiving HEC; breast cancer, colorectal cancer, ovarian cancer, lung cancer, stomach cancer, pancreatic cancer for patients receiving MEC.²² The number of cycles for which NEPA might be eligible for use was derived from the international oncology guidelines of the @sco project.²³

Due to the lack of comparative data of the use of NEPA versus ONDA for patients receiving HEC and MEC and of NEPA versus APR + ONDA and versus fAPR + ONDA for patients receiving MEC, the annual number of cycles of chemotherapies considered excludes the ones assigned to the aforementioned antiemetic treatments (ONDA for HEC and MEC; APR + ONDA and fAPR + ONDA for MEC). The market shares of each antiemetic treatment were derived starting from market analysis and KOL opinions and are reported along with the number of chemotherapy cycles considered for patients receiving HEC and MEC in the online supplementary material.

Resource used and costs

The resource used and the related costs are the same presented in the previous section ('cost-utility analysis').

Sensitivity analysis

A univariate sensitivity analysis was conducted to test the robustness of the results modifying the following parameters: effectiveness emerged in the NEPA study in HEC¹¹ and the NEPA study in MEC,¹² cost of NEPA ($\pm 10\%$), cost of adverse events (assumed to be equal to €0 and increasing the cost of adverse events managed with out-of-pocket resources to be equal to that of the less expensive adverse event considered), cost of CINV event ($\pm 20\%$).

RESULTS

Cost-utility analysis

The use of NEPA lead to a decrease of direct medical costs and to an increase of QALDs compared with APR + PALO and fAPR + PALO for patients receiving both HEC and MEC and to a decrease of direct medical costs and to an increase of QALDs compared with APR + ONDA and fAPR + ONDA for patients receiving HEC, as reported in table 5.

NEPA dominates APR + PALO, fAPR + PALO, APR + ONDA and fAPR + ONDA in patients receiving HEC and dominates APR + PALO, fAPR + PALO in patients receiving MEC.

The sensitivity analysis conducted confirmed the robustness of the results, leading to a domination of NEPA in all the scenario considered, excluding the one in which no intravenous administration cost is considered in the analysis with APR + ONDA, in which NEPA would lead to an increase of costs and to an increase of QALDs. To evaluate whether NEPA is cost effective compared with APR + ONDA for patients receiving HEC, the €/QALD cost-utility ratio was converted in €/QALY. The result shows an ICUR of €64 329/QALY. The ICUR within the population receiving HEC is on the acceptability threshold value of €40 000/QALY identified by the Italian Association of Health Economics,²⁴ therefore, NEPA is not cost-effective compared with APR + ONDA in the scenario that does not consider the resources used by hospitals for intravenous administration of drugs. The dominance of NEPA versus its comparators would not be affected up to a reduction of PALO price of -63% .

Budget impact analysis

In terms of impact on the budget of the Italian National Health Service, the use of NEPA is likely to lead to an annual cost decrease both for patients receiving HEC

Table 5 Results of the cost-utility analysis

| Chemotherapy | Antiemetic therapy | Mean cost (€) | Incremental cost (€) | Mean QALDs | Incremental QALDs | Incremental cost-utility ratio (€/QALD) |
|--------------|--------------------|---------------|----------------------|------------|-------------------|---|
| HEC | APR + PALO | 132.5 | – | 2.684 | – | NEPA is dominant |
| | NEPA | 102.4 | –30.2 | 2.945 | +0.261 | |
| | APR + ONDA | 148.8 | – | 3.020 | – | NEPA is dominant |
| | NEPA | 100.4 | –48.4 | 3.097 | +0.077 | |
| | fAPR + PALO | 155.3 | – | 2.684 | – | NEPA is dominant |
| | NEPA | 102.4 | –52.9 | 2.945 | +0.261 | |
| | fAPR + ONDA | 171.7 | – | 3.020 | – | NEPA is dominant |
| | NEPA | 100.4 | –71.4 | 3.097 | +0.077 | |
| MEC | APR + PALO | 125.1 | – | 2.992 | – | NEPA is dominant |
| | NEPA | 97.9 | –27.2 | 3.044 | +0.052 | |
| | fAPR + PALO | 145.9 | – | 2.992 | – | NEPA is dominant |
| | NEPA | 97.9 | –48.0 | 3.044 | +0.052 | |

APR, aprepitant; fAPR, fosaprepitant; HEC, highly emetogenic chemotherapy; MEC, moderately emetogenic chemotherapy; ONDA, ondansetron; PALO, palonosetron; QALD, quality adjusted life day.




Figure 2 Budget impact analysis results.

and MEC. NEPA would lead to a 5-year cost decrease of €63.7 million (€42.7 million for patients receiving HEC and €20.9 million for patients receiving MEC). The decrease of costs for the Italian National Health Service is due to the increased use of NEPA over the years, being €–2.7 million in 2016, €–7.1 million in 2017, €–9.0 million in 2018, €–11.2 million in 2019, €–12.7 million in 2020 for patients receiving HEC; €–1.4 million in 2016, €–2.5 million in 2017, €–3.7 million in 2018, €–5.5 million in 2019, €–7.9 million in 2020 for patients receiving MEC and €–4.1 million in 2016, €–9.6 million in 2017, €–12.7 million in 2018, €–16.7 million in 2019, €–20.5 million in 2020 for the whole target population (HEC + MEC). The budget impact analysis results are presented in [figure 2](#).

The results of the sensitivity analysis show a minimum 5 years budget impact of €–49.0 million for the whole population (HEC + MEC) in the scenario that does not consider the cost of adverse events and a maximum 5 years budget impact of €–83.9 million in the scenario that considers a reduction of the cost of NEPA of 10%. The use of NEPA would lead to a decrease of costs for the Italian National Health Service in each year of the analysis in every scenario.

DISCUSSION AND CONCLUSION

The cost-utility analysis showed a dominance of NEPA (decreasing costs and increasing incremental QALDs) in patients receiving HEC compared with APR + PALO, fAPR + PALO, APR + ONDA and fAPR + ONDA and in patients receiving MEC compared with APR + PALO and fAPR + PALO.

In terms of sustainability of the investment, the use of NEPA would lead to a decrease of direct medical costs for the Italian National Health Service for the management of patients receiving HEC and MEC on a 5-year basis between €–49.0 million and €–83.9 million.

The sensitivity analyses conducted confirmed the robustness of results.

To our knowledge, the only economic analysis published so far concerning the use of NEPA is a poster presentation by D'Agostino and colleagues¹⁹ in which a cost effectiveness analysis was conducted comparing NEPA with APR + PALO and with PALO to prevent CINV in HEC and MEC patients in UK. NEPA dominates both APR + PALO in patients treated with HEC and PALO in patients treated with MEC and would lead to lower costs for the British NHS on a 5-year time horizon equal to £13.98 million. The results of the aforementioned study are consistent with the findings of our analysis. The lower budget impact reduction of the British study is related to the lower number of market shares considered in terms of market penetration of NEPA, due to the lower number of comparators considered. However, since drugs acquisition costs may vary considerably between countries, as the frequency of CINV episodes, international comparisons should be taken with caution. As an example, Turini and colleagues²⁵ estimated the direct medical costs of severe CINV episodes requiring hospitalisation in three European countries, with an average cost of €389.0 in Italy, €750.1 in France and €1016.7 in Germany.

The analysis presented took into consideration an important topic as that of antiemetic prophylaxis for patients receiving chemotherapy. The importance of

antiemetic prophylaxis is not only related to the possibility to avoid chemotherapies' adverse events with positive effects on the quality of life of patients, on the quality of the health services' performed and on patient's management costs. The lack of prophylaxis, in fact, may lead to future anticipatory emetic events, increasing the adverse events of important and severe therapies as chemotherapy. Furthermore, such anticipatory events, might lead to further prescriptions of tranquilliser and antidepressant drugs with an increase in the drug burden for patients and of costs for the National Health Service.

Due to the expiration of the patent of PALO, generic version of this molecule might be available on the market soon. This factor would reduce the lower costs associated with the use of NEPA unless a price revision for this drug would be proposed. The sensitivity analysis results of the cost-utility Analysis show that up to a 63% reduction of the price of PALO, NEPA would remain dominant in all scenarios.

In conclusion, being aware of the limitations of the model and of the lack of a probabilistic sensitivity analysis, the use of NEPA for the prophylaxis of CINV within the Italian context would lead to an efficient allocation of resources both for the treatment of patients receiving HEC (being dominant compared with APR + PALO, fAPR + PALO, APR + ONDA and fAPR + ONDA) and MEC (being dominant compared with APR + PALO and fAPR + PALO).

The use of NEPA is sustainable in the Italian context, leading to a reduction of costs for the management of patients receiving HEC and MEC.

Author affiliations

¹Centre for Research on Health Economics, Social and Health Care Management (CREMS), Castellanza, Italy

²School of Public Health, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa

³Fondazione IRCCS Istituto Nazionale Tumori, Milan, Italy

⁴Istituto Tumori Giovanni Paolo II, IRCCS, National Cancer Institute, Bari, Italy

⁵Dipartimento dei Servizi, Azienda Sanitaria Locale Roma 3, Rome, Italy

⁶Department of Clinical Science and Community, Section of Medical Statistics, Biometry and Epidemiology "GA Maccacaro", University of Milan, Milan, Italy

⁷Department of Medical Affairs, Italfarmaco Spa, Cinisello Balsamo (MI), Italy

Contributors UR participated in the design of the study, adapted the model, performed the economic analysis and drafted the manuscript. GS, PN, RDT and TP participated in the interpretation of the results and critically revised the article. EB participated in the design of the study, in the model adaptation and helped to draft the manuscript. FS participated in the model adaptation and economic analysis and critically revised the article. DC participated in economic analysis and critically revised the article. LC participated in the design of the study and in the adaptation of the model and helped to draft the manuscript. All authors read and approved the final manuscript.

Funding The analysis and the article drafting were supported by an unconditional grant from Italfarmaco Spa.

Competing interests UR declares advisory board fees from Bayer and Italfarmaco. GS, PN, RDT, FS and DC declare no conflict of interests. EB declares grants from Italfarmaco Spa, Zambon Spa and Polichem SA. TP is employed by Italfarmaco Spa. LC declares personal fees from Italfarmaco Spa and Helsinn Healthcare SA.

Provenance and peer review Not commissioned; externally peer reviewed.

Open Access This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which

permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: <http://creativecommons.org/licenses/by-nc/4.0/>

© Article author(s) (or their employer(s) unless otherwise stated in the text of the article) 2017. All rights reserved. No commercial use is permitted unless otherwise expressly granted.

REFERENCES

- Lorusso D, Bria E, Costantini A, *et al.* Patients' perception of chemotherapy side effects: expectations, doctor-patient communication and impact on quality of life - An Italian survey. *Eur J Cancer Care* 2017;26:e12618.
- Hesketh PJ. Chemotherapy-induced nausea and vomiting. *N Engl J Med* 2008;358:2482-94.
- de Boer-Dennert M, de Wit R, Schmitz PI, *et al.* Patient perceptions of the side-effects of chemotherapy: the influence of 5ht3 antagonists. *Br J Cancer* 1997;76:1055-61.
- MASCC/ESMO, antiemetic guidelines 2016. 2016. <http://www.mascc.org/antiemetic-guidelines>. (accessed 10 Apr 2016).
- Herrstedt J, Roila F, Warr D, *et al.* 2016 updated MASCC/ESMO consensus recommendations: prevention of nausea and Vomiting following high emetic risk chemotherapy. *Support Care Cancer* 2017;25:277-88.
- Basch E, Prestrud AA, Hesketh PJ, *et al.* Antiemetics: American society of clinical oncology clinical practice guideline update. *J Clin Oncol* 2011;29:4189-98.
- NCCN Clinical Practice guidelines in Oncology, Antiemesis v.2.2016. 2016. <http://www.nccn.org>. (accessed 3 Jun 2016).
- Jordan K, Jahn F, Aapro M. Recent developments in the prevention of chemotherapy-induced nausea and vomiting (CINV): a comprehensive review. *Ann Oncol* 2015;26:1081-90.
- Keating GM. Netupitant/Palonosetron: a review in the prevention of chemotherapy-induced nausea and vomiting. *Drugs* 2015;75:2131-41.
- Celio L, Niger M, Ricchini F, *et al.* Palonosetron in the prevention of chemotherapy-induced nausea and vomiting: an evidence-based review of safety, efficacy, and place in therapy. *Core Evid* 2015;10:75-87.
- Hesketh PJ, Rossi G, Rizzi G, *et al.* Efficacy and safety of NEPA, an oral combination of netupitant and Palonosetron, for prevention of chemotherapy-induced nausea and vomiting following highly emetogenic chemotherapy: a randomized dose-ranging pivotal study. *Ann Oncol* 2014;25:1340-6.
- Aapro M, Rugo H, Rossi G, *et al.* A randomized phase III study evaluating the efficacy and safety of NEPA, a fixed-dose combination of netupitant and Palonosetron, for prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy. *Ann Oncol* 2014;25:1328-33.
- de Wit R, Schmitz PI, Verweij J, *et al.* Analysis of cumulative probabilities shows that the efficacy of 5HT₃ antagonist prophylaxis is not maintained. *J Clin Oncol* 1996;14:644-51.
- de Wit R, Herrstedt J, Rapoport B, *et al.* Addition of the oral NK1 antagonist aprepitant to standard antiemetics provides protection against nausea and vomiting during multiple cycles of cisplatin-based chemotherapy. *J Clin Oncol* 2003;21:4105-11.
- Gralla RJ, Bosnjak SM, Hontsa A, *et al.* A phase III study evaluating the safety and efficacy of NEPA, a fixed-dose combination of netupitant and Palonosetron, for prevention of chemotherapy-induced nausea and vomiting over repeated cycles of chemotherapy. *Ann Oncol* 2014;25:1333-9.
- Aapro M, Karthaus M, Schwartzberg L, *et al.* NEPA, a fixed oral combination of netupitant and palonosetron, improves control of chemotherapy-induced nausea and vomiting (CINV) over multiple cycles of chemotherapy: results of a randomized, double-blind, phase 3 trial versus oral palonosetron. *Support Care Cancer* 2017;25:1127-35.
- EUnetHTA Joint Action 2, Work Package 8. HTA Core Model ® version 2.1 (Pdf). 2015. <http://www.corehta.info/BrowseModel.aspx>
- Ruckert A, Labonté R. The global financial crisis and health equity: early experiences from Canada. *Global Health* 2014;10:2.
- D'agostino P, Cawston H, Bourhis F, *et al.* Fixed combination netupitant and palonosetron is a cost-effective intervention for the prevention of chemotherapy-induced nausea and vomiting in the UK. *Value Health* 2015;18:A461.
- Longo F, Mansueto G, Lapadula V, *et al.* Combination of aprepitant, palonosetron and dexamethasone as antiemetic prophylaxis in

- lung cancer patients receiving multiple cycles of cisplatin-based chemotherapy. *Int J Clin Pract* 2012;66:753–7.
21. Sullivan SD, Mauskopf JA, Augustovski F, *et al*. Budget impact analysis—principles of good practice: report of the ISPOR 2012 Budget Impact analysis good practice II Task Force. *Value Health* 2014;17:5–14.
 22. World Health Organization. GLOBOCAN 2012: estimated cancer incidence, mortality and prevalence Worldwide. 2012 http://globocan.iarc.fr/Pages/burden_sel.aspx.
 23. Progetto @sco. Aggiornamento Delle Linee Guida Internazionali in Oncologia. <https://www.progettoasco.it/category/linee-guida/aggiornamento-delle-linee-guida-internazionali/oncologia/>.
 24. Italian Health Economics Association (AIES). Proposta di Linee-Guida per la valutazione economica degli interventi sanitari. *Politiche Sanitarie* 2009;10:91–9.
 25. Turini M, Piovesana V, Ruffo P, *et al*. An assessment of chemotherapy-induced nausea and vomiting direct costs in three EU countries. *Drugs Context* 2015;4:1–6.
 26. Gralla R, Lichinitser M, Van Der Vegt S, *et al*. Palonosetron improves prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy: results of a double-blind randomized phase III trial comparing single doses of palonosetron with ondansetron. *Ann Oncol* 2003;14:1570–7.
 27. Akynzeo® Prescribing Information. 2015. https://www.akynzeo.com/assets/pdf/Prescribing_Information.pdf (accessed 4 Nov 2016)
 28. EMA. Akynzeo Summary of product Characteristic. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/003728/WC500188432.pdf (accessed 3 Nov 2016).
 29. Hesketh PJ, Rossi G, Rizzi G, *et al*. Efficacy of NEPA, a novel combination of netupitant and palonosetron of chemotherapy induced nausea and vomiting following highly emetogenic chemotherapy. *J Clin Oncol* 2013 31:578s. abstract 9512.
 30. EMA. Emend Summary of product characteristics. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000527/WC500026537.pdf (accessed 3 Nov 2016).
 31. EMA. Aloxi Summary of product characteristics. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000563/WC500024259.pdf (accessed 3 Nov 2016).
 32. FDA. Ivemend Summary of product Characteristic. http://www.accessdata.fda.gov/drugsatfda_docs/label/2016/022023s006lbl.pdf (accessed 3 Nov 2016).
 33. Agenzia Italiana del Farmaco. Determina 15 febbraio 2016. Riclassificazione Del medicinale per uso umano «Akynzeo», ai sensi dell'articolo 8, comma 10, della legge 24 dicembre 1993, n. 537. (Determina n. 245/2016). (16A01599) (GU Serie Generale n.51 del 2-3-2016). http://www.gazzettaufficiale.it/atto/serie_generale/caricaDettaglioAtto/originario;jsessionid=r2r+h7+A0NM6Lm41Jk6Bw__ntc-as3-guri2b?atto.dataPubblicazioneGazzetta=2016-03-02&atto.codiceRedazionale=16A01599&elenco30giorni=false (accessed 3 Nov 2016).
 34. Agenzia Italiana del Farmaco. Determina 30 ottobre 2014. Riclassificazione Del medicinale per uso umano «Ivemend (fosaprepitant)» ai sensi dell'articolo 8, comma 10, della legge 24 dicembre 1993, n. 537. (Determina n. 1250/2014). (14A08736) (GU Serie Generale n.265 del 14-11-2014). http://www.gazzettaufficiale.it/eli/id/2014/11/14/14A08736/sg;jsessionid=g1UFhJGio1kuYGqwvgXPAQ__ntc-as1-guri2a (accessed 3 Nov 2016).
 35. Agenzia Italiana del Farmaco. Determina 30 ottobre 2014. Riclassificazione Del medicinale per uso umano «Ivemend (fosaprepitant)» ai sensi dell'articolo 8, comma 10, della legge 24 dicembre 1993, n. 537. (Determina n. 1250/2014). (14A08736) (GU Serie Generale n.265 del 14-11-2014). http://www.gazzettaufficiale.it/eli/id/2014/11/14/14A08736/sg;jsessionid=g1UFhJGio1kuYGqwvgXPAQ__ntc-as1-guri2a (accessed 3 Nov 2016).
 36. Agenzia Italiana del Farmaco. Comunicato. Autorizzazione all'immissione in commercio del medicinale «Ondansetron Accord Healthcare». <http://www.gazzettaufficiale.biz/atti/2011/201110108/11A05682.htm> (accessed 3 Nov 2016).
 37. Agenzia Italiana del Farmaco. Determinazione 27 febbraio 2006. regime di rimborsabilità e prezzo di vendita della specialità medicinale Aloxi «palonosetron», autorizzata con procedura centralizzata europea dalla Commissione europea. (Determinazione/C n. 82/2006) (Gazzetta n. 54 del 6 marzo 2006). <http://www.gazzettaufficiale.biz/atti/2006/20060054/06A02127.htm> (accessed 3 Nov 2016).
 38. Agenzia Italiana del Farmaco. Autorizzazione all'immissione in commercio del medicinale «Decadron». Estratto determinazione n. 715/2012 del 28 maggio 2012. Supplemento ordinario n. 123 alla Gazzetta Ufficiale Serie generale 141. http://www.gazzettaufficiale.it/do/atto/serie_generale/caricaPdf?cdimg=12A0662600000010110001&cdgu=2012-06-19&art.dataPubblicazioneGazzetta=2012-06-19&art.codiceRedazionale=12A06626&art.num=1&art.tiposerie=SG (accessed 3 Nov 2016).
 39. Grunberg SM, Boutin N, Ireland A, *et al*. Impact of nausea/vomiting on quality of life as a visual analogue scale-derived utility score. *Support Care Cancer* 1996;4:435–9.
 40. Lordick F, Ehlken B, Ihbe-Heffinger A, *et al*. Health outcomes and cost-effectiveness of aprepitant in outpatients receiving antiemetic prophylaxis for highly emetogenic chemotherapy in Germany. *Eur J Cancer* 2007;43:299–307.
 41. Annemans L, Strens D, Lox E, *et al*. Cost-effectiveness analysis of aprepitant in the prevention of chemotherapy-induced nausea and vomiting in Belgium. *Support Care Cancer* 2008;16:905–15.
 42. Parker M, Haycox A, Graves J. Estimating the relationship between preference-based generic utility instruments and disease-specific quality-of-life measures in severe chronic constipation: challenges in practice. *Pharmacoeconomics* 2011;29:719–30.
 43. Stafford MR, Hareendran A, Ng-Mak DS, *et al*. EQ-5D™-derived utility values for different levels of migraine severity from a UK sample of migraineurs. *Health Qual Life Outcomes* 2012;10:65.
 44. Attard CL, Brown S, Alloul K, *et al*. Cost-effectiveness of folirinox for first-line treatment of metastatic pancreatic Cancer. *Curr Oncol* 2014;21:41–51.
 45. Waugh N, Cummins E, Shyangdan DS, *et al*. *Exenatide prolonged-release suspension for injection in combination with oral antidiabetic therapy for the treatment of type 2 diabetes*. National Institute for Health and Clinical Excellence, 2012.
 46. Purdum AG, Globe D, Mathes A, *et al*. Pcn15: differences between preferences for health states: the chemotherapy adverse event self-assessed response (CAESAR) QUESTIONNAIRE. *Value in Health* 2001;4:89–90.

Correction: *Cost-utility and budget impact analyses of the use of NEPA for chemotherapy-induced nausea and vomiting prophylaxis in Italy*

Restelli U, Saibene G, Nardulli P, *et al.* Cost-utility and budget impact analyses of the use of NEPA for chemotherapy-induced nausea and vomiting prophylaxis in Italy. *BMJ Open* 2017;**7**:e015645. doi: 10.1136/bmjopen-2016-015645.

There is an error in Supplementary file 1. In the first table of the supplementary material, Annex 1, in row MEC, -2.5 and -4.4 in column ' Δ NEPA - APR+PALO (%)' should be +2.5 and +4.4, respectively.

Open Access This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: <http://creativecommons.org/licenses/by-nc/4.0/>

© Article author(s) (or their employer(s) unless otherwise stated in the text of the article) 2017. All rights reserved. No commercial use is permitted unless otherwise expressly granted.

BMJ Open 2017;**7**:e015645corr1. doi:10.1136/bmjopen-2016-015645corr1



CrossMark